Sahar Iftikhar Iftikhar

Ms. Sahar Iftikhar Iftikhar

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 March 2026 in Cancer Medicine
Verified
Journal Article
Open access
SISahar Iftikhar Iftikhar
Sahar Iftikhar Iftikhar
EBElissa Burr
Elissa Burr
AFAmal Freigoun
Amal Freigoun
TNTheo Nearney
Theo Nearney
CKChristelle Q. Kanda
Christelle Q. Kanda
VSValerie Speirs
Valerie Speirs
Background: Breast cancer (BC) in men accounts for less than 1% of all BC diagnoses worldwide. Despite its low incidence, the number of men being diagnosed is increasing. Historically perceived as a predominantly female disease, BC in men has received comparatively limited attention. Aim: This review aims to examine how BC manifests in men and explored the impact of stigma and awareness on diagnosis and prognosis. Methods: A narrative review of current literature was undertaken, including epidemiological studies, clinical research and psychosocial analyses relating to male BC. Results: Male BC shares several pathological and molecular features with female BC, but notable differences exist in presentation, tumour biology and treatment considerations. Men are more likely to present at a later stage of disease, often due to low awareness and misconception that BC affects only women. Stigma and limited targeted education further contribute to delayed medical consultation. Discussion: Although understanding of male BC has improved, challenges remain in early detection and awareness. The gendered perception of BC may discourage men from seeking timely medical advice, leading to more advanced disease at diagnosis and potentially poorer outcomes. Conclusion: Addressing stigma, increasing public and professional education and promoting clinical research inclusive of men are essential to improving timely diagnosis and outcomes.

28 August 2026 in Current Oncology
Verified
Journal Article
Open access
PDF file
SISahar Iftikhar Iftikhar
Sahar Iftikhar Iftikhar
AXAlex Xiao
Alex Xiao
Zhaohui JinZhaohui Jin
Zhaohui Jin
EAEmad H Aly
Emad H Aly
Purpose: This review aims to provide an updated overview of Kirsten rat sarcoma viral oncogene homologue (KRAS) mutations in colorectal carcinoma (CRC), focusing on their role in tumorigenesis, prognostic implications, and recent advances in targeted therapy. Major findings: KRAS mutations occur in approximately 40% of colorectal cancers and play a central role in tumour initiation and progression through constitutive activation of MAPK pathways. Clinically, KRAS mutations are well established as predictors of resistance to anti-EGFR therapy. Increasing evidence also supports their role as prognostic biomarkers, with KRAS-mutant tumours associated with increased recurrence risk and reduced survival, including in patients undergoing hepatic metastasectomy. Therapeutically, recent advances, most notably KRAS G12C inhibitors and combination strategies targeting upstream or parallel pathways, have expanded treatment options, although efficacy varies across KRAS mutation subtypes. Conclusions: KRAS mutations have important implications for the behaviour, prognosis, and management of colorectal cancer. Integrating KRAS mutational status into clinical decision-making may enable more personalised prognostication and treatment strategies. Continued research is required to broaden effective targeted therapies for the diverse spectrum of KRAS-mutant disease.